GLAXO WELLCOME VALTREX POSTS $7.8 MIL. IN SALES AFTER SEPTEMBER LAUNCH; ZANTAC SALES DOWN 4%; GLAXO PREDICTS FOUR PRODUCT LAUNCHES FOR THIS YEAR
Glaxo Wellcome's Valtrex contributed $7.8 mil. (œ5 mil.) in U.S. sales in 1995 after its September launch. FDA approved Valtrex for shingles in June and for recurrent genital herpes in December. Worldwide sales of Valtrex (valacyclovir) were $14 mil., CEO Richard Sykes told a meeting of securities analysts in New York City March 7.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth